Shares of GSK plc (LON:GSK – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seven analysts that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is GBX 1,842.50 ($24.11).
A number of equities research analysts have issued reports on GSK shares. Citigroup cut their price target on GSK from GBX 2,120 ($27.75) to GBX 1,900 ($24.87) and set a “buy” rating for the company in a research note on Friday, July 5th. Berenberg Bank reissued a “buy” rating and issued a GBX 1,820 ($23.82) price target on shares of GSK in a report on Tuesday, September 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a GBX 1,850 ($24.21) price objective on shares of GSK in a report on Tuesday, September 3rd. Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,100 ($27.48) target price on shares of GSK in a report on Thursday, June 27th. Finally, Shore Capital reiterated a “buy” rating on shares of GSK in a research note on Wednesday, August 28th.
Get Our Latest Stock Report on GSK
GSK Price Performance
GSK Dividend Announcement
The business also recently disclosed a dividend, which was paid on Thursday, October 10th. Shareholders of record on Thursday, August 15th were paid a dividend of GBX 15 ($0.20) per share. The ex-dividend date was Thursday, August 15th. This represents a yield of 0.97%. GSK’s payout ratio is currently 5,309.73%.
Insider Buying and Selling at GSK
In related news, insider Elizabeth (Liz) McKee Anderson bought 446 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were purchased at an average price of GBX 2,051 ($26.84) per share, with a total value of £9,147.46 ($11,971.55). Company insiders own 1.61% of the company’s stock.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Read More
- Five stocks we like better than GSK
- Investing In Preferred Stock vs. Common Stock
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.